Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).
It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).
It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).
Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).
Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).
Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).
It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).
VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).
It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).
VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).